PL2819516T3 - Zastosowanie (1 R,5S-(+)-1-(naftalen-2-ylo)-3-azabicyklo{3.1.0}heksanu w leczeniu stanów wywołanych przez neuroprzekaźniki monoaminowe - Google Patents

Zastosowanie (1 R,5S-(+)-1-(naftalen-2-ylo)-3-azabicyklo{3.1.0}heksanu w leczeniu stanów wywołanych przez neuroprzekaźniki monoaminowe

Info

Publication number
PL2819516T3
PL2819516T3 PL12820058T PL12820058T PL2819516T3 PL 2819516 T3 PL2819516 T3 PL 2819516T3 PL 12820058 T PL12820058 T PL 12820058T PL 12820058 T PL12820058 T PL 12820058T PL 2819516 T3 PL2819516 T3 PL 2819516T3
Authority
PL
Poland
Prior art keywords
naphthalen
azabicyclo
hexane
treatment
monoamine neurotransmitters
Prior art date
Application number
PL12820058T
Other languages
English (en)
Polish (pl)
Inventor
Anthony Alexander Mckinney
Frank Bymaster
Original Assignee
Otsuka America Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka America Pharmaceutical, Inc. filed Critical Otsuka America Pharmaceutical, Inc.
Publication of PL2819516T3 publication Critical patent/PL2819516T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL12820058T 2011-07-30 2012-07-27 Zastosowanie (1 R,5S-(+)-1-(naftalen-2-ylo)-3-azabicyklo{3.1.0}heksanu w leczeniu stanów wywołanych przez neuroprzekaźniki monoaminowe PL2819516T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161574231P 2011-07-30 2011-07-30
US201113334066A 2011-12-22 2011-12-22
US201213528940A 2012-06-21 2012-06-21
EP12820058.1A EP2819516B1 (fr) 2011-07-30 2012-07-27 Utilisation de (1r,5s)-(+)-l-(naphthalèn-2-yl)-3-azabicyclo{3.1.0}hexane dans le cadre du traitement d'affections associées aux neurotransmetteurs mono-amine
PCT/US2012/000335 WO2013019271A1 (fr) 2011-07-30 2012-07-27 Utilisation de (lr,5s)-(+)-l-(naphthalèn-2-yl)-3-azabicyclo[3.1.0]hexane dans le cadre du traitement d'affections associées aux neurotransmetteurs mono-amine

Publications (1)

Publication Number Publication Date
PL2819516T3 true PL2819516T3 (pl) 2020-08-10

Family

ID=47629575

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12820058T PL2819516T3 (pl) 2011-07-30 2012-07-27 Zastosowanie (1 R,5S-(+)-1-(naftalen-2-ylo)-3-azabicyklo{3.1.0}heksanu w leczeniu stanów wywołanych przez neuroprzekaźniki monoaminowe

Country Status (12)

Country Link
EP (1) EP2819516B1 (fr)
CA (1) CA2843847C (fr)
CY (1) CY1122773T1 (fr)
DK (1) DK2819516T3 (fr)
ES (1) ES2779032T3 (fr)
HR (1) HRP20200424T1 (fr)
HU (1) HUE048715T2 (fr)
LT (1) LT2819516T (fr)
PL (1) PL2819516T3 (fr)
PT (1) PT2819516T (fr)
SI (1) SI2819516T1 (fr)
WO (1) WO2013019271A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613943B1 (pt) 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa
US9133159B2 (en) * 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US9839627B2 (en) * 2013-12-09 2017-12-12 Neurovance, Inc. Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
CA2989431C (fr) * 2015-06-17 2023-08-29 Franklin Bymaster Composes cristallins
CA3026794A1 (fr) 2016-06-28 2018-01-04 Trichomeshell Ltd. Forme pharmaceutique destinee a etre vaporisee et fumee
WO2018119291A1 (fr) * 2016-12-21 2018-06-28 Otsuka America Pharmaceutical, Inc. Procédés de synthèse
TW202412768A (zh) 2022-09-02 2024-04-01 日商大塚製藥股份有限公司 以1-(萘-2-基)-3-氮雜雙環[3.1.0]己烷治療中樞神經系統病症之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20050096395A1 (en) * 2002-02-12 2005-05-05 Rao Srinivas G. Methods of treating attention deficit/hyperactivity disorder (adhd)
BRPI0613943B1 (pt) * 2005-07-27 2021-06-22 Otsuka America Pharmaceutical, Inc Composto, composição farmacêutica o compreendendo, usos de um composto e de uma composição farmacêutica, bem como composição neurobiologicamente ativa

Also Published As

Publication number Publication date
EP2819516A4 (fr) 2016-01-20
EP2819516A1 (fr) 2015-01-07
HUE048715T2 (hu) 2020-09-28
EP2819516B1 (fr) 2019-12-25
ES2779032T3 (es) 2020-08-13
CA2843847C (fr) 2021-05-18
PT2819516T (pt) 2020-03-25
LT2819516T (lt) 2020-05-25
HRP20200424T1 (hr) 2020-09-04
DK2819516T3 (da) 2020-03-16
SI2819516T1 (sl) 2020-07-31
CY1122773T1 (el) 2021-05-05
WO2013019271A1 (fr) 2013-02-07
CA2843847A1 (fr) 2013-02-07

Similar Documents

Publication Publication Date Title
EP2819516A4 (fr) Utilisation de (1r,5s)-(+)-l-(naphthalèn-2-yl)-3-azabicyclo{3.1.0}hexane dans le cadre du traitement d'affections associées aux neurotransmetteurs mono-amine
IN2014CN02616A (fr)
EP2646019A4 (fr) Préparation et utilisation du (+)-1-(3,4-dichlorophényl)-3-azabicyclo- [3.1.0]hexane dans le traitement des pathologies affectées par les neurotransmetteurs de type monoamine
SG11201400113XA (en) Microorganisms and methods for producing 2,4-pentadienoate, butadiene, propylene, 1,3-butanediol and related alcohols
EP2699091A4 (fr) Composés de 2',6'-dioxo-3'-deutéro-pipéridin-3-yl-isoindoline
IL230635A (en) An outgrowth of 4,3,2,1-tetrahydroquinoline used to treat diabetes
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
ZA201402907B (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
IL232710B (en) l-serine preparations, methods and uses for the treatment of neurodegenerative diseases and disorders
HK1192757A1 (zh) 取代的 -芳基- -苯基- -三嗪- -胺
HK1206938A1 (en) Process for the preparation of 3-chloro-4,5,6-trifluoro- picolinonitrile 3--456--
EP2890370A4 (fr) Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
EP2720708A4 (fr) Ciblage de la jonction neuromusculaire pour un traitement
WO2012027482A3 (fr) Composés, compositions et méthodes associés aux antagonistes des ppar
IL232194A (en) An iontophoresis cross-linking preparation for use in keratoconus treatment
IL231468A0 (en) 3,1-diaryl-converted heterocyclic pesticides
LT2882724T (lt) Junginiai, skirti naudoti susirgimų, kurie yra palengvinami slopinant hdac, gydymui
IL228891A (en) 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease
EP2994129A4 (fr) Utilisation de (+)-1-(3,4-dichlorophényl)-3-azabicyclo[3.1.0]hexane pour traiter les troubles addictifs et associés à l'alcool
AU2017202012A1 (en) Preparation and use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo(3.1.0)hexane in the treatment of conditions affected by monoamine neurotransmitters
UY4159Q (es) Motocicleta
ITFI20100058U1 (it) Telaio bicicletta smontabile "wirebike3".
IT1401957B1 (it) Composizione per il trattamento dell'acne.
PL394344A1 (pl) Inhibitor wychwytu zwrotnego serotoniny, jego zastosowanie i sposób syntezy